Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine for coronary slow flow syndrome
IRCT20220516054874N6Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Slow Coronary Flow (SCF) comparing Ranolazine plus common treatments with Placebo plus common treatments (2 arms). Started Oct 2022; status: completed.
02
Drugs
ranolazine
03
Conditions
Slow Coronary Flow (SCF)
Beyond the preview
Go deeper on IRCT20220516054874N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220516054874N6.